Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study

被引：3

作者：

Gutner, Cassidy A. ^{[1
]}

van der Valk, Marc ^{[2
,3
]}

Portilla, Joaquin ^{[4
]}

Jeanmaire, Eliette ^{[5
]}

Belkhir, Leila ^{[6
]}

Lutz, Thomas ^{[7
]}

Demoor, Rebecca ^{[8
]}

Trehan, Rekha ^{[9
]}

Scherzer, Jenny ^{[10
]}

Pascual-Bernaldez, Miguel ^{[11
]}

Ait-Khaled, Mounir ^{[9
]}

Hernandez, Beatriz ^{[11
]}

de Ruiter, Annemiek ^{[9
]}

Anand, Savita Bakhshi ^{[12
]}

Low, Emma L. ^{[12
]}

Hadi, Monica ^{[12
]}

Barnes, Nicola ^{[12
]}

Sevdalis, Nick ^{[13
]}

Mohammed, Perry ^{[9
]}

Czarnogorski, Maggie ^{[1
]}

机构：

[1] ViiV Healthcare, Durham, NC USA

[2] Univ Amsterdam, Med Ctr, Dept Infect Dis, Amsterdam, Netherlands

[3] Amsterdam Inst Infect & Immun, Amsterdam, Netherlands

[4] Hosp Gen Univ Dr Balmis Alicante, Alicante, Spain

[5] CHRU Nancy, Hop Brabois, Serv Malad Infect & Trop, Vandoeuvre Les Nancy, France

[6] Clin Univ St Luc, Brussels, Belgium

[7] Infektiologikum, Frankfurt, Germany

[8] GSK, Collegeville, PA USA

[9] ViiV Healthcare, London, England

[10] ViiV Healthcare, Munich, Germany

[11] ViiV Healthcare, Madrid, Spain

[12] Evidera, London, England

[13] Natl Univ Singapore, Ctr Behav & Implementat Sci Intervent, Yong Loo Lin Sch Med, Singapore, Singapore

来源：

JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE | 2024年 / 23卷

关键词：

cabotegravir plus rilpivirine; long-acting; acceptability; satisfaction; stigma; appropriateness; HIV;

D O I：

10.1177/23259582241269837

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction CARISEL is an implementation-effectiveness "hybrid" study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months (Q2M) across 5 European countries.Methods PSPs completed questionnaires on acceptability (Acceptability of Intervention Measure), appropriateness (Intervention Appropriateness Measure), and feasibility (Feasibility of Intervention Measure) at their first (Month [M] 1), third (M4), and seventh (M12) injection visits. Semistructured qualitative interviews were also conducted.Results Overall, 437 PSPs were enrolled, of whom 430 received treatment. Median (interquartile range) age was 44 (37-51) years, 25.3% (n = 109/430) were female (sex at birth), and 21.9% (n = 94/430) were persons of color. Across time points, PSPs found CAB + RPV LA highly acceptable, appropriate, and feasible (mean scores >= 4.47/5). Qualitative data supported these observations.Conclusions PSPs found CAB + RPV LA Q2M to be an acceptable, appropriate, and feasible treatment option.

引用

页数：11

共 33 条

[1]

Ahmed S.K., 2024, Journal of Medicine, Surgery, and Public Health, P100051, DOI DOI 10.1016/J.GLMEDI.2024.100051

[2] Adherence to HIV treatment regimens: systematic literature review and meta-analysis [J].

Altice, Frederick ;

Evuarherhe, Obaro ;

Shina, Sophie ;

Carter, Gemma ;

Beaubrun, Anne Christine .

PATIENT PREFERENCE AND ADHERENCE, 2019, 13 :475-490

[3]

[Anonymous], 2005, GUIDELINES USE ANTIR

[4]

[Anonymous], 2022, Guidelines Version 11.1-European AIDS Clinical Society

[5] Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) [J].

Chounta, Vasiliki ;

Overton, Edgar T. ;

Mills, Anthony ;

Swindells, Susan ;

Benn, Paul D. ;

Vanveggel, Simon ;

van Solingen-Ristea, Rodica ;

Wang, Yuanyuan ;

Hudson, Krischan J. ;

Shaefer, Mark S. ;

Margolis, David A. ;

Smith, Kimberly Y. ;

Spreen, William R. .

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (06) :849-862

[6] Reflections on 10 years of effectiveness-implementation hybrid studies [J].

Curran, Geoffrey M. ;

Landes, Sara J. ;

McBain, Sacha A. ;

Pyne, Jeffrey M. ;

Smith, Justin D. ;

Fernandez, Maria E. ;

Chambers, David A. ;

Mittman, Brian S. .

FRONTIERS IN HEALTH SERVICES, 2022, 2

[7] Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE) [J].

Czarnogorski, Maggie ;

Garris, Cindy P. ;

Dalessandro, Marybeth ;

D'Amico, Ronald ;

Nwafor, Toyin ;

Williams, Will ;

Merrill, Deanna ;

Wang, YuanYuan ;

Stassek, Larissa ;

Wohlfeiler, Michael B. ;

Sinclair, Gary I. ;

Mena, Leandro A. ;

Thedinger, Blair ;

Flamm, Jason A. ;

Benson, Paul ;

Spreen, William R. .

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 (09)

[8] Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection [J].

D'Amico, Ronald ;

Margolis, David A. .

CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) :13-18

[9] Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives Study [J].

de Los Rios, Patricia ;

Okoli, Chinyere ;

Castellanos, Erika ;

Allan, Brent ;

Young, Benjamin ;

Brough, Garry ;

Muchenje, Marvelous ;

Eremin, Anton ;

Corbelli, Giulio Maria ;

McBritton, Marta ;

Hardy, W. David ;

Van de Velde, Nicolas .

AIDS AND BEHAVIOR, 2021, 25 (03) :961-972

[10]

European Medicines Agency, VOCABRIA PRODUCT INF

← 1 2 3 4 →